세계의 암 면역치료 Drug Discovery 아웃소싱 시장 규모, 점유율 및 동향 분석 보고서 : 약물 유형별, 암 유형별, 서비스 유형별, 지역별, 부문별 예측(2023-2030년)

Cancer Immunotherapy Drug Discovery Outsourcing Market Growth & Trends:

The global cancer immunotherapy drug discovery outsourcing market size is expected to reach USD 2.5 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 9.8% from 2023 to 2030. The main drivers of this market are the increasing prevalence of cancer Worldwide, increasing investment by pharmaceutical and biotechnology companies in cancer research, and the rise in awareness among people for advanced treatment of cancer.

In the early stages of the COVID-19 pandemic, there was a halt in the growth of the cancer immunotherapy drug discovery market. This decrease in cancer immunotherapy drug discovery is due to the influx of a large number of patients that are infected with COVID-19 and require immediate intensive care and treatment. Also, disruptions in the supply chain, travel restrictions to prevent pandemics, and strict regulations have resulted in delays in the cancer immunotherapy drug discovery market. However, this impact will be significantly reduced by adopting strategic methods taken by pharmaceutical companies and regulatory authorities.

Other drivers of the market are the rising demand for outsourcing of drug discovery, which is increasing rapidly due to low cost as compared to in-house R&D costs, and the use of a tax credit that allows several benefits. For instance, reduces problems that are generally encountered with taxation authorities and it allows pharmaceutical and biotechnology companies to plan effectively their global projects with CRO. Also, the governments are actively participating and taking initiatives for cancer treatment. For instance, in April 2022, the government of India launched 17 hospitals for the treatment of cancer. This is a joint initiative taken by Tata trust and the government, to create an affordable cancer care network.

Also, there is the development of various new molecules for cancer immunotherapy and new immunotherapeutic options such as checkpoint inhibitors, immunomodulators, tumor-infiltrating lymphocytes, and CAR-T cell therapy. Several others are still in the pipeline to check their efficacy against cancer.

Cancer Immunotherapy Drug Discovery Outsourcing Market Report Highlights:

• The monoclonal antibodies segment dominated the market and accounted for the largest revenue share of 63.0% in 2022. This growth is due to high efficacy and a rise in regulatory approvals
• The lead screening and characterization segment is expected to grow at the fastest CAGR during the forecast period. This is due to a rise in new and effective ways to decrease the time for effective assays in this segment
• The lung cancer segment accounted for the largest revenue share of 24.5% in 2022. This rise is due to the large number of prevalent effective immunotherapies for this cancer type
• North America dominated the market and accounted for a revenue share of 36.2% in 2022. This is due to a rise in demand for new technologies and an increasing incidence of cancer in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Service type
  • 1.1.2. Cancer type
  • 1.1.3. Drug type
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Service type outlook
  • 2.2.2. Cancer type outlook
  • 2.2.3. Drug type outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cancer Immunotherapy Drug Discovery Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Cancer Immunotherapy Drug Discovery Outsourcing Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Cancer Immunotherapy Drug Discovery Outsourcing: Drug Type Estimates & Trend Analysis

• 4.1. Cancer Immunotherapy Drug Discovery Outsourcing Market: Key Takeaways
• 4.2. Cancer Immunotherapy Drug Discovery Outsourcing Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Monoclonal Antibodies
  • 4.3.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Immunomodulators
  • 4.4.1. Immunomodulators market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Cancer Vaccines and Oncolytic Viral Therapy
  • 4.5.1. Cancer vaccines and oncolytic viral therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cancer Immunotherapy Drug Discovery Outsourcing: Service Type Estimates & Trend Analysis

• 5.1. Cancer Immunotherapy Drug Discovery Outsourcing Market: Key Takeaways
• 5.2. Cancer Immunotherapy Drug Discovery Outsourcing Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Target Identification and Validation
  • 5.3.1. Target identification and validation market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Lead Screening and Characterization
  • 5.4.1. Lead screening and characterization market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Cell-based Assays
  • 5.5.1. Cell-based assays market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cancer Immunotherapy Drug Discovery Outsourcing: Cancer Type Estimates & Trend Analysis

• 6.1. Cancer Immunotherapy Drug Discovery Outsourcing Market: Key Takeaways
• 6.2. Cancer Immunotherapy Drug Discovery Outsourcing Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Lung
  • 6.3.1. Lung market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Breast
  • 6.4.1. Breast market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Colorectal
  • 6.5.1. Colorectal market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Melanoma
  • 6.6.1. Melanoma market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Prostate
  • 6.7.1. Prostate market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Head & Neck
  • 6.8.1. Head & Neck market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. Ovarian
  • 6.9.1. Ovarian market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.10. Pancreatic
  • 6.10.1. Pancreatic market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cancer Immunotherapy Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Outlook
• 7.2. Cancer Immunotherapy Drug Discovery Outsourcing Market by Region: Key Takeaway
• 7.3. North America
  • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.3. France
    • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.6. Sweden
    • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.2. China
    • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.3. India
    • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.7. MEA
  • 7.7.1. Saudi Arabia
    • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Market Participant Categorization
  • 8.2.1. Explicyte Immuno-Oncology
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Aquila Biomedical
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Horizon Discovery Group plc
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Crown Bioscience Inc.
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Promega Corporation
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. HD Co. Ltd.
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. BPS Biosciences Inc.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Gen script Biotech Corporation
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Celentyx Ltd.
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. ImmuneXperts SA
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Personalis
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Product benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. STC Biologics
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Product benchmarking
    • 8.2.12.4. Strategic initiatives
  • 8.2.13. Molecular Imaging Inc. (MI Bioresearch Inc.)
    • 8.2.13.1. Company overview
    • 8.2.13.2. Financial performance
    • 8.2.13.3. Product benchmarking
    • 8.2.13.4. Strategic initiatives
  • 8.2.14. Covance, Inc.
    • 8.2.14.1. Company overview
    • 8.2.14.2. Financial performance
    • 8.2.14.3. Product benchmarking
    • 8.2.14.4. Strategic initiatives